Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 7 OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4 Thoracic 2 CNS 2 Tumor-Agnostic 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1 Neoplasms 1

Interventions

Paclitaxel 192 Carboplatin 159 pembrolizumab 118 Bevacizumab 86 liposomal doxorubicin 68 Gemcitabine 62 Cisplatin 55 olaparib 49 Topotecan 47 Nivolumab 32 niraparib 30 Cyclophosphamide 30 Doxorubicin 29 Docetaxel 26 1-dodecylpyridoxal 22 Injections 21 Drug Therapy 20 human papillomavirus vaccine, L1 type 16, 18 19 fludarabine 18 atezolizumab 18 Pemetrexed 18 lenvatinib 17 mirvetuximab soravtansine 16 Fulvestrant 16 avelumab 15 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15 durvalumab 14 Oxaliplatin 13 Irinotecan 13 Fluorouracil 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × nimotuzumab × Gynecologic × Clear all

NCT03413579 2021-08-25

CIMAHOPE

El Kendi Pharmaceuticals Manufacturing Company

Phase 3 Completed

Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡